Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
Sponsor: Nanjing Leads Biolabs Co.,Ltd
Summary
This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.
Official title: A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
468
Start Date
2023-04-14
Completion Date
2026-03-31
Last Updated
2025-05-07
Healthy Volunteers
No
Conditions
Interventions
LBL-033 for Injection
Initial dose - MTD; Q2W; intravenous infusion
Locations (6)
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
West China Second University Hospital,Sichuan University
Chengdu, Sichuan, China